Invesco Pharmaceuticals ETF
PJP
93 hedge funds and large institutions have $59M invested in Invesco Pharmaceuticals ETF in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
14% more capital invested
Capital invested by funds: $51.8M → $59M (+$7.22M)
1% more funds holding
Funds holding: 92 → 93 (+1)
0.05% less ownership
Funds ownership: 22.28% → 22.23% (-0.05%)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$730K |
| 2 |
Goldman Sachs
New York
|
+$635K |
| 3 |
LPL Financial
San Diego,
California
|
+$510K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$477K |
| 5 |
WI
WBI Investments
Red Bank,
New Jersey
|
+$472K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$799K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$651K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$545K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$408K |
| 5 |
SWGC
Summit Wealth Group (Colorado)
Colorado Springs,
Colorado
|
-$366K |
PJP Hedge Fund Activity: Q3 2025 in Review
93 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q3 2025, worth a combined $59M — up 14% from $51.8M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PJP positions and 7 closed out — a net gain of 1 holder — while 19 added to existing stakes and 23 trimmed.
The largest buyer was Ameriprise, adding an estimated $730K. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $799K sold.
- 93 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q3 2025, up from 92 in Q2 2025.
- Funds reported $59M of Invesco Pharmaceuticals ETF stock for Q3 2025, up 14% quarter-over-quarter.
- 8 funds opened new Invesco Pharmaceuticals ETF positions in Q3 2025 and 7 closed out, a net change of +1 holder.
- The largest Invesco Pharmaceuticals ETF buyer in Q3 2025 was Ameriprise, an estimated $730K added.
- The largest Invesco Pharmaceuticals ETF seller in Q3 2025 was BNP Paribas Financial Markets, an estimated $799K sold.
Based on aggregated 13F filings for Q3 2025.